Insights Into Acute Myeloid Leukemia (AML)

Perspectives of community physicians on the treatment of AML

Central – March 25, 2023
Purchase Report

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Northeast – August 2023
Purchase Report

Faculty Chair

TBC

TBC

Midwest – October 2023
Purchase Report

Faculty Chair

TBC

TBC

Northwest – November 2023
Purchase Report

Faculty Chair

TBC

TBC

More Information

  • Houston, TX
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Baltimore, MD
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Chicago, IL
  • Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of AML
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.